Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transparency Life Sciences (TLS) has entered into a licensing contract with Stanford University for the use of lisinopril as a treatment for multiple sclerosis (MS).
Subscribe to our email newsletter
The protocol template of the Phase II trial of lisinopril is currently available on a prototype of the company’s crowdsourced web platform.
The web platform allows patients, physicians, researchers and others to participate in the design of clinical studies for compounds that TLS has in-licensed for development.
Crowdsourcing is being employed to design clinical protocols with the participation of patients and physicians which will allow focusing on those parameters most relevant to actual clinical practice, the company said.
Transparency will utilise telemedicine and related technologies to reduce burdens on clinical trial subjects, enhance data quality and reduce costs.
TLS will demonstrate how data transparency can accelerate and improve the drug development process.
TLS CEO Tomasz Sablinski said lisinopril is an inexpensive and effective drug that has been used safely by millions of people around the world to control their high blood pressure.
"Lisinopril is an ideal candidate for our strategy of radically redesigning the clinical trial process to assess the potential of drugs that might otherwise never be tested," Sablinski added.